Public Sector Pension Investment Board lifted its holdings in shares of Biogen Inc. (NASDAQ:BIIB - Free Report) by 10,085.8% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,466,095 shares of the biotechnology company's stock after acquiring an additional 2,441,884 shares during the quarter. Biogen accounts for about 1.2% of Public Sector Pension Investment Board's holdings, making the stock its 13th largest position. Public Sector Pension Investment Board owned about 1.67% of Biogen worth $557,042,000 at the end of the most recent quarter.
A number of other hedge funds have also bought and sold shares of BIIB. BlackRock Inc. purchased a new position in shares of Biogen during the 2nd quarter valued at $3,453,878,000. Primecap Management Co. CA bought a new position in shares of Biogen during the 2nd quarter worth $3,274,304,000. Wellington Management Group LLP increased its holdings in Biogen by 5.3% in the 2nd quarter. Wellington Management Group LLP now owns 3,117,469 shares of the biotechnology company's stock worth $673,560,000 after acquiring an additional 155,828 shares during the last quarter. Russell Investments Group Ltd. increased its holdings in Biogen by 1,524.5% in the 3rd quarter. Russell Investments Group Ltd. now owns 2,175,055 shares of the biotechnology company's stock worth $491,301,000 after acquiring an additional 2,041,161 shares during the last quarter. Finally, Pictet Asset Management Holding SA increased its holdings in Biogen by 139.4% in the 3rd quarter. Pictet Asset Management Holding SA now owns 2,039,056 shares of the biotechnology company's stock worth $460,582,000 after acquiring an additional 1,187,237 shares during the last quarter. 87.93% of the stock is currently owned by institutional investors.
Latest Biogen News
Investors following BIIB have been watching these news items:
- Positive Sentiment: New Phase 2 data for investigational anti-tau drug diranersen showed increasing benefit over two years in early Alzheimer’s disease, including slower decline across cognition, function and disease-progression measures. The twice-yearly 60 mg dose had the largest effects. The findings are encouraging but still require confirmation in later-stage trials. Read the diranersen announcement
- Positive Sentiment: Biogen’s Q3 growth portfolio revenue rose 49% year over year, while core pharmaceutical revenue totaled $2 billion. That growth may help offset pressure on older products and strengthen the company’s revenue outlook. Read the investor takeaways
- Negative Sentiment: Investors bought 6,120 BIIB put options Tuesday, about 232% above the average volume. This may reflect increased hedging or bearish positioning, but options activity alone does not establish market direction.
Analyst Upgrades and Downgrades
BIIB has been the topic of several recent research reports. Stifel Nicolaus set a $242.00 price objective on shares of Biogen in a report on Thursday, September 10th. Wedbush lifted their target price on shares of Biogen from $212.00 to $225.00 and gave the stock a "neutral" rating in a research note on Thursday, October 29th. Mizuho boosted their price target on shares of Biogen from $221.00 to $241.00 and gave the company an "outperform" rating in a research report on Tuesday, August 4th. Needham & Company LLC boosted their price target on shares of Biogen from $256.00 to $290.00 and gave the company a "buy" rating in a research report on Thursday, October 29th. Finally, Zacks Research upgraded shares of Biogen from a "strong sell" rating to a "hold" rating in a research note on Tuesday, July 28th. One investment analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $254.41.
Get Our Latest Analysis on Biogen
Biogen Stock Down 0.3%
Shares of NASDAQ BIIB opened at $250.79 on Wednesday. The company has a quick ratio of 1.37, a current ratio of 1.95 and a debt-to-equity ratio of 0.39. The company has a market cap of $37.07 billion, a P/E ratio of 107.18, a P/E/G ratio of 2.85 and a beta of 0.10. Biogen Inc. has a 52 week low of $160.36 and a 52 week high of $261.00. The business has a 50-day simple moving average of $234.73 and a two-hundred day simple moving average of $205.80.
Biogen (NASDAQ:BIIB - Get Free Report) last announced its quarterly earnings results on Wednesday, October 28th. The biotechnology company reported $2.62 earnings per share for the quarter, beating the consensus estimate of $1.99 by $0.63. Biogen had a return on equity of 9.38% and a net margin of 3.37%. The firm had revenue of $2.80 billion for the quarter, compared to analysts' expectations of $2.63 billion. During the same period in the prior year, the business posted $4.81 earnings per share. The company's revenue was up 10.6% on a year-over-year basis. Research analysts anticipate that Biogen Inc. will post 12.46 earnings per share for the current fiscal year.
About Biogen
(
Free Report)
Biogen is a biotechnology company focused on developing and commercializing medicines for neurological and rare diseases. Its areas of focus include multiple sclerosis, Alzheimer's disease, spinal muscular atrophy and Friedreich's ataxia. Its products include multiple sclerosis treatments such as Tysabri, Tecfidera and Vumerity, and Skyclarys for Friedreich's ataxia. Biogen shares rights to several medicines with other companies, including Leqembi for Alzheimer's disease with Eisai and Spinraza for spinal muscular atrophy with Ionis Pharmaceuticals.
Featured Articles
Want to see what other hedge funds are holding BIIB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Biogen Inc. (NASDAQ:BIIB - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Biogen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Biogen wasn't on the list.
While Biogen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.